Global In-vivo CRO Industry: Key Statistics and Insights in 2024-2032

Summary:

• The global in-vivo CRO market size reached USD 4.9 Billion in 2023.
• The market is expected to reach USD 9.3 Billion by 2032, exhibiting a growth rate (CAGR) of 7.12% during 2024-2032.
• North America leads the market, accounting for the largest in-vivo CRO market share.
• Rodent accounts for the majority of the market share in the type segment due to its relatively short lifespans and rapid reproduction rates.
• GLP toxicology holds the largest share in the in-vivo CRO industry.
• Oncology remains a dominant segment in the market owing to the growing number of oncology drug candidates entering clinical trials.
• The rising cost for drug development is a primary driver of the in-vivo CRO market.
• The growing preclinical research activities is reshaping the in-vivo CRO market.

Industry Trends and Drivers:

• Rising drug development costs:

Drug development has become more intricate due to advancements in science and technology. Modern therapeutics, especially biologics and personalized medicine, require more extensive in-vivo studies, which can be costly. As a result, pharmaceutical companies often outsource these complex studies to specialized CROs that have the necessary expertise and resources. The pharmaceutical industry faces constant pressure to minimize the costs associated with drug development while maintaining high standards of quality and compliance. By outsourcing in-vivo studies to CROs, companies can reduce overhead costs, such as maintaining in-house facilities and staff, leading to more efficient budget management.

• Growing preclinical research activities:

The growing pipeline of drug candidates, particularly in the fields of biotechnology and personalized medicine, has led to an increased demand for preclinical studies, which often require in-vivo testing. Pharmaceutical and biotech companies are investing heavily in early-stage research, resulting in more in-vivo studies being outsourced to CROs. As drug development becomes more complex, especially with biologics, gene therapies, and advanced therapeutics, the need for rigorous preclinical testing, including in-vivo studies, is heightened. CROs possess the expertise and infrastructure to conduct these complex studies efficiently, making them preferred partners for companies looking to validate their drug candidates.

• Technological advancements:

Advanced imaging techniques allow for more precise monitoring of physiological and pathological processes in live subjects. This results in more reliable data on drug efficacy and safety. The integration of genomic and biomarker technologies enables better identification of suitable models and more accurate predictions of drug responses, improving the reliability of in-vivo studies. Development of sophisticated in-vivo models, including genetically modified animals and humanized models, provides more relevant data for human drug development. The use of automation in laboratory settings streamlines processes, such as dosing and monitoring, reducing human error and improving study efficiency.

Request for a sample copy of this report: https://www.imarcgroup.com/in-vivo-cro-market/requestsample

In-vivo CRO Market Report Segmentation:

Breakup By Type:

• Rodent
  • Rats
  • Mice
  • Others
• Non-Rodent

Rodent represents the largest segment due to its cost-effectiveness, well-characterized genetics, and the extensive availability of strain-specific data.

Breakup By GLP Type:

• Non-GLP
  • In House
  • Outsourcing
• GLP Toxicology
  • In House
  • Outsourcing

GLP toxicology accounts for the majority of the market share. GLP Toxicology studies are critical for regulatory submissions, necessitating comprehensive safety assessments of drug candidates, which drives their prevalence and dominance in the in-vivo CRO market.

Breakup By Indication:

• Autoimmune/Inflammation Conditions
  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Osteoarthritis
  • Irritable Bowel Syndrome
  • Others
• Pain Management
  • Chronic Pain
  • Acute Pain
• Oncology
  • Blood Cancer
  • Solid Tumor
  • Others
• CNS Conditions
  • Epilepsy
  • Parkinson’s Disease
  • Huntington’s Disease
  • Stroke
  • Traumatic Brain Injury
  • ALS
  • Muscle Regeneration
  • Others
• Diabetes
• Obesity
• Others

Oncology exhibits a clear dominance in the market owing to the rising prevalence of cancer and the increasing number of oncology drug candidates in development lead to a high demand for in-vivo studies focused on tumor models and therapeutic efficacy.

Breakup By Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America enjoys the leading position in the in-vivo CRO market. North America is home to a large number of pharmaceutical and biotechnology companies, significant research funding, and a robust regulatory framework.

Top In-vivo CRO Market Leaders:

The in-vivo CRO market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:

• Charles River Laboratories International Inc.
• Evotec SE
• ICON plc
• Iris Pharma (Abionyx Pharma)
• Labcorp Drug Development (Laboratory Corporation of America Holdings)
• North American Science Associates LLC
• Parexel International Corporation
• Pharmaceutical Product Development Inc. (Thermo Fisher Scientific Inc.)
• Pronexus Analytical AB
• Syneos Health
• WuXi AppTec.

Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145